|
1
|
Kanwal M, Ding XJ and Cao Y: Familial risk
for lung cancer. Oncol Lett. 13:535–542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stinchcombe TE and Socinski MA: Current
treatments for advanced stage non-small cell lung cancer. Proc Am
Thorac Soc. 6:233–241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu
Y, Chen Y, Xu L, Zen K, Zhang C and Shen H: Serum microRNA
signatures identified in a genome-wide serum microRNA expression
profiling predict survival of non-small-cell lung cancer. J Clin
Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Combes G, Alharbi I, Braga LG and Elowe S:
Playing polo during mitosis: PLK1 takes the lead. Oncogene.
34:4819–4827. 2017. View Article : Google Scholar
|
|
6
|
Song B, Liu XS and Liu X: Polo-like kinase
1 (Plk1): An unexpected player in DNA replication. Cell Div.
7:32012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Z, Sun Q and Wang X: PLK1, a potential
target for cancer therapy. Transl Oncol. 10:22–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu C, Li S, Chen T, Hu H, Ding C, Xu Z,
Chen J, Liu Z, Lei Z, Zhang HT, et al: miR-296-5p suppresses cell
viability by directly targeting PLK1 in non-small cell lung cancer.
Oncol Rep. 35:497–503. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang XH, Lu Y, Liang JJ, Cao JX, Jin YQ,
An GS, Ni JH, Jia HT and Li SY: MiR-509-3-5p causes aberrant
mitosis and anti-proliferative effect by suppression of PLK1 in
human lung cancer A549 cells. Biochem Biophys Res Commun.
478:676–682. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang H, Tian C, Xu Y, Xie WL, Zhang J,
Zhang BY, Ren K, Wang K, Chen C, Wang SB, et al: Abortive cell
cycle events in the brains of scrapie-infected hamsters with
remarkable decreases of PLK3/Cdc25C and increases of PLK1/cyclin
B1. Mol Neurobiol. 48:655–668. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
King SI, Purdie CA, Bray SE, Quinlan PR,
Jordan LB, Thompson AM and Meek DW: Immunohistochemical detection
of Polo-like kinase-1 (PLK1) in primary breast cancer is associated
with TP53 mutation and poor clinical outcom. Breast Cancer Res.
14:R402012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takahashi T, Sano B, Nagata T, Kato H,
Sugiyama Y, Kunieda K, Kimura M, Okano Y and Saji S: Polo-like
kinase 1 (PLK1) is overexpressed in primary colorectal cancers.
Cancer Sci. 94:148–152. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Medema RH, Lin CC and Yang JC: Polo-like
kinase 1 inhibitors and their potential role in anticancer therapy,
with a focus on NSCLC. Clin Cancer Res. 17:6459–6466. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo J and Liu X: Polo-like kinase 1, on
the rise from cell cycle regulation to prostate cancer development.
Protein Cell. 3:182–197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun W, Su Q, Cao X, Shang B, Chen A, Yin H
and Liu B: High expression of polo-like kinase 1 is associated with
early development of hepatocellular carcinoma. Int J Genomics.
2014:3121302014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ito Y, Yoshida H, Matsuzuka F, Matsuura N,
Nakamura Y, Nakamine H, Kakudo K, Kuma K and Miyauchi A: Polo-like
kinase 1 (PLK1) expression is associated with cell proliferative
activity and cdc2 expression in malignant lymphoma of the thyroid.
Anticancer Res. 24:259–263. 2004.PubMed/NCBI
|
|
17
|
Zhang G, Zhang Z and Liu Z: Polo-like
kinase 1 is overexpressed in renal cancer and participates in the
proliferation and invasion of renal cancer cells. Tumour Biol.
34:1887–1894. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao
QF, Zong YP, Feng B, Zheng MH and Lu AG: Polo-like kinase 1 is
over-expressed in colorectal cancer and participates in the
migration and invasion of colorectal cancer cells. Med Sci Monit.
18:BR237–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Z, Zhang G and Kong C: High
expression of polo-like kinase 1 is associated with the metastasis
and recurrence in urothelial carcinoma of bladder. Urol Oncol.
31:1222–1230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao M, Gao FH, Wang JY, Liu F, Yuan HH,
Zhang WY and Jiang B: JAK2/STAT3 signaling pathway activation
mediates tumor angiogenesis by upregulation of VEGF and bFGF in
non-small-cell lung cancer. Lung Cancer. 73:366–374. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu Y, Zhao Q, Wang Z and Liu XY: Activated
STAT3 correlates with prognosis of non-small cell lung cancer and
indicates new anticancer strategies. Cancer Chemother Pharmacol.
75:917–922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-beta-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morry J, Ngamcherdtrakul W, Gu S, Reda M,
Castro DJ, Sangvanich T, Gray JW and Yantasee W: Targeted treatment
of metastatic breast cancer by PLK1 siRNA delivered by an
antioxidant nanoparticle platform. Mol Cancer Ther. 4:763–772.
2017. View Article : Google Scholar
|
|
24
|
Xu L, Zhou R, Yuan L, Wang S, Li X, Ma H,
Zhou M, Pan C, Zhang J and Huang N: IGF1/IGF1R/STAT3
signaling-inducible IFITM2 promotes gastric cancer growth and
metastasis. Cancer Lett. 393:76–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y: Reciprocal Activation between
PLK1 and Stat3 contributes to survival and proliferation of
esophageal cancer cells. Gastroenterology. 142:5212012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pomerening JR: Positive-feedback loops in
cell cycle progression. FEBS Lett. 583:3388–3396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fossey SL, Bear MD, Kisseberth WC, Pennell
M and London CA: Oncostatin M promotes STAT3 activation, VEGF
production, and invasion in osteosarcoma cell lines. BMC Cancer.
11:1252011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang L, Song X, Zhu J, Li M, Ji Y, Wu F,
Chen Y, Cui X, Hu J, Wang L, et al: Tumor suppressor microRNA-34a
inhibits cell migration and invasion by targeting
MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. Int J
Oncol. 51:3782017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gong J, Zhu S, Zhang Y and Wang J:
Interplay of VEGFa and MMP2 regulates invasion of glioblastoma.
Tumor Biol. 35:11879–11885. 2014. View Article : Google Scholar
|
|
31
|
Kesanakurti D, Chetty C, Dinh DH, Gujrati
M and Rao JS: Role of MMP-2 in the regulation of IL-6/Stat3
survival signaling via interaction with α٥β١ integrin in glioma.
Oncogene. 32:327–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shen X, Tang J, Hu J, Guo L, Xing Y and Xi
T: MiR-424 regulates monocytic differentiation of human leukemia
U937 cells by directly targeting CDX2. Biotechnol Lett.
35:1799–1806. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hsu F, Caluwe AD, Anderson D, Nichol A,
Toriumi T and Ho C: Patterns of spread and prognostic implications
of lung cancer metastasis in an era of driver mutations. Curr
Oncol. 24:228–233. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter
RJ and Yang SF: Cancer metastasis: Mechanisms of inhibition by
melatonin. J Pineal Res. 62:e123702017. View Article : Google Scholar
|
|
35
|
Scott BJ, Oberheimbush NA and Kesari S:
Leptomeningeal metastasis in breast cancer-a systematic review.
Oncotarget. 4:3740–3747. 2016.
|
|
36
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Inhibition of invasion and MMPs by a nutrient
mixture in human cancer cell lines: A correlation study. Exp Oncol.
32:243–248. 2010.PubMed/NCBI
|
|
37
|
Groblewska M, Mroczko B, Gryko M, Kedra B
and Szmitkowski M: Matrix metalloproteinase 2 and tissue inhibitor
of matrix metalloproteinases 2 in the diagnosis of colorectal
adenoma and cancer patients. Folia Histochem Cytobiol. 48:564–571.
2010.PubMed/NCBI
|
|
38
|
Duan W, Li R, Ma J, Lei J, Xu Q, Jiang Z,
Nan L, Li X, Wang Z, Huo X, et al: Overexpression of Nodal induces
a metastatic phenotype in pancreatic cancer cells via the Smad2/3
pathway. Oncotarget. 6:1490–1506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Y, Pan T, Zhong X and Cheng C:
Androgen receptor promotes esophageal cancer cell migration and
proliferation via matrix metalloproteinase 2. Tumour Biol.
36:5859–5864. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng H, Takahashi H, Murai Y, Cui Z,
Nomoto K, Niwa H, Tsuneyama K and Takano Y: Expressions of MMP-2,
MMP-9 and VEGF are closely linked to growth, invasion, metastasis
and angiogenesis of gastric carcinoma. Anticancer Res.
26:3579–3583. 2006.PubMed/NCBI
|
|
41
|
Zhu Y, Yu X, Fu H, Wang P, Zheng X and
Wang Y: MicroRNA-21 is involved in ionizing radiation-promoted
liver carcinogenesis. Int J Clin Exp Med. 3:2112010.PubMed/NCBI
|
|
42
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nature Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shibata MA, Morimoto J, Shibata E and
Otsuki Y: Combination therapy with short interfering RNA vectors
against VEGF-C and VEGF-A suppresses lymph node and lung metastasis
in a mouse immunocompetent mammary cancer model. Cancer Gene Ther.
15:776–786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miao JW, Liu LJ and Huang J:
Interleukin-6-induced epithelial-mesenchymal transition through
signal transducer and activator of transcription 3 in human
cervical carcinoma. Int J Oncol. 45:165–176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yan LI, Li LI, Li Q, DI W, Shen W, Zhang L
and Guo H: Expression of signal transducer and activator of
transcription 3 and its phosphorylated form is significantly
upregulated in patients with papillary thyroid cancer. Exp Ther
Med. 9:2195–2201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li C, Wang Z, Liu Y, Wang P and Zhang R:
STAT3 expression correlates with prognosis of thymic epithelial
tumors. J Cardiothoracic Surg. 8:922013. View Article : Google Scholar
|
|
47
|
Park JK, Hong R, Kim KJ, Lee TB and Lim
SC: Significance of p-STAT3 expression in human colorectal
adenocarcinoma. Oncol Rep. 20:597–604. 2008.PubMed/NCBI
|
|
48
|
Zhang M, Zhu GY, Gao HY, Zhao SP and Xue
Y: Expression of tissue levels of matrix metalloproteinases and
tissue inhibitors of metalloproteinases in gastric adenocarcinoma.
J Surg Oncol. 103:243–247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zheng F, Malureanu L, Huang J, Wang W, Li
H, van Deursen JM, Tindall DJ and Chen J: Plk1-dependent
phosphorylation of FoxM1 regulates a transcriptional programme
required for mitotic progression. Nat Cell Biol. 9:1076–1082.
2008.
|
|
50
|
Dibb M, Han N, Choudhury J, Hayes S,
Valentine H, West C, Ang YS and Sharrocks AD: The FOXM1-PLK1 axis
is commonly upregulated in oesophageal adenocarcinoma. Brit J
Cancer. 107:1766–1775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Guo K, Yin G, Zi X-H and Yan W-G: A study
on expression and Tyrosine 705 phosphorylation of STAT3 in focal
cerebral ischemia-reperfusion rat model and its role in neuronal
apoptosisTrop J Pharma Res. 2. pp. 2672016, View Article : Google Scholar
|
|
52
|
Shin SB, Woo SU, Chin YW, Jang YJ and Yim
H: Sensitivity of TP53-Mutated cancer cells to the Phytoestrogen
Genistein is associated with direct inhibition of Plk1 activity. J
Cell Physiol. 232:2818–2828. 2017. View Article : Google Scholar : PubMed/NCBI
|
